Alzinova is pioneering the development of the first ever oligomer-specific vaccine against Alzheimer’s disease
Alzheimer’s affects every society across the World. An active vaccine that treats the underlying cause of the disease has the potential to change that, to the benefit of both individuals and society. There are few therapies that can compete with vaccines when it comes to convenience, patient adherence, and as a means to globally prevent and treat disease.
Positron emission tomography (PET) imaging of Aβ plaques using the PiB tracer. Alzheimer brain (left) and normal brain (right). Image courtesy of Prof A. Nordberg, KI, Sweden.
Drug development against Alzheimer’s disease
Alzheimer’s disease in a lethal neurodegenerative disorder afflicting on the order of 40 million people world wide. It is generally considered to be one of the areas of medicine where there is the largest unmet medical need, as there are no disease-modifying drugs available. Novel therapeutics which exhibit even moderate efficacy will not only ease the suffering of those afflicted, but also generate large savings for society.
The AβCC peptide in hairpin conformation. Picture courtesy of Prof. T. Härd, SLU, Sweden.
The AβCC Peptide™ Technology
Alzinova’s products have been developed using the proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process.
Specific Targeting of Aβ Toxins, “Oligomers”
Alzinova’s mission is to bring true disease-modifying therapy to Alzheimer’s disease patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.
We are dedicated to developing novel disease-modifying treatments to enable patients to live an independent life free from Alzheimer’s disease. Alzinova’s lead candidate, ALZ-101, is in late preclinical development as a therapeutic vaccine for the treatment of Alzheimer’s. Alzinova’s antibody, ALZ-201, is in early preclinical development. The portfolio is generated from the proprietary AβCC peptide™ technology and targets the toxic Aβ oligomers specifically.